Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help
Search by PDB author
1HQ0
DownloadVisualize
BU of 1hq0 by Molmil
CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF E.COLI CYTOTOXIC NECROTIZING FACTOR TYPE 1
Descriptor: CYTOTOXIC NECROTIZING FACTOR 1, PHOSPHATE ION
Authors:Buetow, L, Flatau, G, Chiu, K, Boquet, P, Ghosh, P.
Deposit date:2000-12-13
Release date:2001-07-04
Last modified:2024-02-07
Method:X-RAY DIFFRACTION (1.83 Å)
Cite:Structure of the Rho-activating domain of Escherichia coli cytotoxic necrotizing factor 1.
Nat.Struct.Biol., 8, 2001
1HZG
DownloadVisualize
BU of 1hzg by Molmil
CRYSTAL STRUCTURE OF THE INACTIVE C866S MUTANT OF THE CATALYTIC DOMAIN OF E. COLI CYTOTOXIC NECROTIZING FACTOR 1
Descriptor: CYTOTOXIC NECROTIZING FACTOR 1, PHOSPHATE ION
Authors:Buetow, L, Flatau, G, Chiu, K, Boquet, P, Ghosh, P.
Deposit date:2001-01-24
Release date:2001-07-04
Last modified:2023-08-09
Method:X-RAY DIFFRACTION (1.86 Å)
Cite:Structure of the Rho-activating domain of Escherichia coli cytotoxic necrotizing factor 1.
Nat.Struct.Biol., 8, 2001
8Z8V
DownloadVisualize
BU of 8z8v by Molmil
Crystal structure of human serum albumin in complex with ALB8(VHH) domain of ozoralizumab
Descriptor: ALB8:VHH, Serum albumin
Authors:Mima, M, Mishima-Tsumagari, C.
Deposit date:2024-04-22
Release date:2024-09-04
Last modified:2024-10-30
Method:X-RAY DIFFRACTION (2.05 Å)
Cite:Structural design of the anti-TNF alpha therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy.
Biochem.Biophys.Res.Commun., 734, 2024
8Z8M
DownloadVisualize
BU of 8z8m by Molmil
Crystal structure of human TNF alpha in complex with TNF30(VHH) domain of ozoralizumab
Descriptor: TNF30:VHH, Tumor necrosis factor
Authors:Mima, M, Mishima-Tsumagari, C.
Deposit date:2024-04-22
Release date:2024-09-04
Last modified:2024-10-30
Method:X-RAY DIFFRACTION (2.59 Å)
Cite:Structural design of the anti-TNF alpha therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy.
Biochem.Biophys.Res.Commun., 734, 2024

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon